Key Takeaways DHR's Life Sciences segment's revenues are likely to drop 3.4% on weak demand in key end markets. Diagnostics performance is expected to be hurt by soft molecular test demand and lower China sales. Biotechnology revenues are projected to rise 7% on strong bioprocessing and discovery business demand.Danaher Corporation (DHR) is scheduled to release second-quarter 2025 results on July 22, before market open.The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates a ...

Key Takeaways TSCO's Q2 earnings are likely to see strong demand for consumable, usable and edible merchandise. Market share gains and rural-focused assortments support TSCO's recent momentum. ONETractor and the Neighbor's Club program are driving customer engagement and sales.Tractor Supply Company (TSCO) is likely to register an increase in the top line when it reports second-quarter 2025 results on July 24, before market open. The Zacks Consensus Estimate for revenues is pegged at $4.40 billion, indica ...

Good morning. My name is Rob, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Dollar General first quarter 2025 earnings call. Today is Tuesday, June 3rd, 2025. All lines have been placed on mute to prevent background noise. This call is being recorded. Instructions for listening to the replay of the call are available in the company's earnings press release issued this morning. Now, I'd like to turn the conference over to Mr. Kevin Walker, Vice President, Inves ...

Core Viewpoint - 10x Genomics, Inc. will report its financial results for Q2 2025 on August 7, 2025, and will host a conference call to discuss these results and future outlook [1]. Group 1: Financial Reporting - The financial results for the second quarter ended June 30, 2025, will be announced after market close on August 7, 2025 [1]. - A public conference call and live webcast for analysts and investors will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1]. Group 2: Company Overview - 10x Genomics is a life science technology company focused on products that enhance the understanding of biology and improve human health [3]. - The company offers integrated research solutions, including instruments, consumables, and software for single cell and spatial biology, aiding researchers in comprehending complex biological systems [3]. - Its products contribute to advancements in various fields such as oncology, immunology, and neuroscience, leading to significant discoveries in health and disease [3]. Group 3: Disclosure Practices - 10x Genomics utilizes various channels, including SEC filings, press releases, and social media, to disclose material non-public information and comply with disclosure obligations [4].

Core Insights - STERIS plc's Healthcare segment is benefiting from strong market adoption of its infection prevention products and capital equipment, while the Applied Sterilization Technologies (AST) division is seeing solid growth due to increased service revenues [1][4][5] - The company has shown resilience in its stock performance, with a 6.2% increase over the past year, contrasting with a 12.2% decline in the industry [2] - STERIS has a market capitalization of $22.88 billion and an earnings yield of 4.4%, outperforming the industry's -2.9% [2] Healthcare Segment Performance - The Healthcare segment reported a 5% year-over-year revenue growth for the fourth quarter of fiscal 2025, driven by a 6% increase in consumable revenues and a 13% growth in service revenues [4] - The segment achieved a 6% constant currency organic revenue growth for the fiscal fourth quarter, with order growth exceeding 12% [4][8] - Margins improved due to increased volume, favorable pricing, and positive productivity, which offset labor inflation [4] AST Segment Growth - The AST division experienced a 9% year-over-year growth in the fiscal fourth quarter, supported by a 6% increase in service revenues [5] - The division is gaining traction with ethylene oxide sterilization, particularly among manufacturers of single-use sterile technologies for vaccines and biopharmaceuticals [5] - Constant currency organic revenues in the AST segment were in the high single digits, indicating strong demand from bioprocessing and stable global demand from MedTech customers [5] Financial Health - As of the fiscal fourth quarter of 2025, STERIS reduced its long-term debt by 38.5% to $1.92 billion from $3.12 billion a year earlier [6][9] - The company ended the fiscal third quarter with cash and cash equivalents of $171.7 million, exceeding its short-term debt of $125 million [6] - The total debt-to-capital ratio was 22.5%, down 33.2% year over year, indicating improved solvency [9] Challenges Facing the Company - The global macroeconomic environment has negatively impacted STERIS' financial operations, with rising healthcare costs and procurement challenges affecting production costs [10] - Customer consolidation due to competitive pressures and cost reduction measures has led to pricing pressure and potential customer loss for STERIS [11] Earnings Estimates - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings has increased by 0.9% to $10.11, with revenues projected at $5.83 billion, suggesting a 6.7% growth from fiscal 2024 [12]

CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET to review its financial results for the second quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company’s website ...

Core Insights - The near-term outlook for the Zacks Industrial Services industry is positive, driven by increasing e-commerce activity and a recent rise in the production index [1][5] - Companies like Siemens, MSC Industrial Direct, and Eos Energy Enterprises are strategically positioned to leverage these trends through cost-cutting, operational efficiency improvements, and investments in automation and digitization [2] Industry Overview - The Zacks Industrial Services industry includes companies providing industrial equipment products and MRO services, serving diverse sectors such as commercial, government, healthcare, and manufacturing [3] - The industry focuses on reducing MRO supply-chain costs and enhancing productivity through inventory management and procurement solutions [3] Trends Impacting the Industry - E-commerce is expected to drive growth, with global e-commerce revenues projected to grow at a CAGR of 18.9% from 2024 to 2030, and the U.S. market at a CAGR of 16.4% [4] - The manufacturing sector, contributing around 70% to the industry's revenues, has shown signs of recovery with the production index entering expansion territory at 50.3% in June, up from 45.4% in May [5] Cost Management Strategies - The industry faces significant inflation, including rising labor, freight, and fuel costs, prompting companies to implement pricing actions, cost-cutting measures, and productivity improvements [6] Market Performance - The Zacks Industrial Services industry has outperformed both its sector and the S&P 500 over the past year, growing 16.5% compared to the sector's 14.8% and the S&P 500's 11.2% [9] - The industry currently trades at a forward 12-month EV/EBITDA ratio of 30.7X, significantly higher than the S&P 500's 13.89X and the Industrial Products sector's 19.94X [12] Company Highlights - Siemens reported a 10% increase in orders and a 7% rise in revenues in Q2, bolstered by acquisitions that enhance its capabilities in industrial AI and simulation [18][19] - Eos Energy Enterprises secured a $22.7 million loan advance to support its production expansion, with projected revenues for 2025 between $150 million and $190 million, up from $15.7 million in 2024 [21][22] - MSC Industrial noted positive trends in its fiscal third quarter, focusing on long-term growth objectives and recent acquisitions to enhance its market position [25]

Company Overview - DENTSPLY SIRONA Inc. is a global leader in the design, development, manufacture, and marketing of dental consumables, dental laboratory products, dental specialty products, and consumable medical device products [11] - The company also provides dental technology products, including dental implants, scanning equipment, treatment software, and orthodontic appliances, as well as dental equipment such as treatment centers and imaging equipment [11] Investment Rating - DENTSPLY SIRONA Inc. has a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong potential for investment [12] - The company has a Momentum Style Score of B, with shares increasing by 0.7% over the past four weeks [12] Earnings Estimates - Three analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.03 to $1.90 per share [12] - DENTSPLY SIRONA Inc. has an average earnings surprise of +2.7%, suggesting positive performance relative to expectations [12] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DENTSPLY SIRONA Inc. is recommended for investors' consideration [13]

Financial Performance - Q1 2013 - Net sales decreased by 1.2%, from $727.1 million in Q1 2012 to $718.6 million in Q1 2013[6] - Operating income decreased by 3.3%, from $91.7 million in Q1 2012 to $88.6 million in Q1 2013[6] - Adjusted operating income increased by 8.4%, from $91.7 million in Q1 2012 to $99.3 million in Q1 2013[6] - Net income increased by 4.0%, from $64.2 million in Q1 2012 to $66.8 million in Q1 2013[6] - Adjusted net income increased significantly by 20.1%, from $64.2 million in Q1 2012 to $77.1 million in Q1 2013[6] - Diluted EPS increased by 5.3%, from $0.76 in Q1 2012 to $0.80 in Q1 2013[6] - Adjusted diluted EPS increased by 21.1%, from $0.76 in Q1 2012 to $0.92 in Q1 2013[6] Segment Performance - North America welding segment net sales increased by 10.0%, from $381.3 million to $419.6 million, with an adjusted EBIT margin of 17.1%[16] - Europe welding segment net sales decreased by 12.2%, from $125.8 million to $110.5 million, with an adjusted EBIT margin of 9.3%[18] - Asia Pacific welding segment net sales decreased significantly by 24.3%, from $92.6 million to $70.0 million, but the adjusted EBIT margin increased to 3.1%[20] - The Harris Products Group net sales decreased by 6.3%, from $87.6 million to $82.1 million, but the adjusted EBIT margin improved to 8.5%[25] Capital Allocation - The company contributed $50 million to the U.S pension plan[29] - Share repurchases amounted to $12.8 million[30]

DOWNERS GROVE, Ill., July 8, 2025 /PRNewswire/ -- Dover (NYSE: DOV) announced today that it will release second quarter 2025 earnings at approximately 6:00 a.m. Central time (7:00 a.m. Eastern time) on Thursday, July 24, 2025. Later that morning, Dover will host a conference call at 8:30 a.m. Central time (9:30 a.m. Eastern time) to discuss these results.To participate in the conference call, please dial 1 (800) 225-9448 (domestic) or 1 (203) 518-9708 (international), conference ID DOVQ225. Due to the expec ...